Physician profile
Cornelius Toma
NPI 1003966482
$1,985.47
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $23.57.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $384.34 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $237.86 | 2019 | |
| Allergan, INC. | $180.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $157.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.06 | 2019 | |
| Lilly USA, LLC | $122.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $122.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.21 | 2019 | |
| Glaxosmithkline, LLC. | $90.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.49 | 2019 | |
| Amgen INC. | $79.11 | 2019 | |
| Sunovion Pharmaceuticals INC. | $46.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $44.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.39 | 2019 | |
| Endo Pharmaceuticals INC. | $26.41 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $24.32 | 2019 | |
| Supernus Pharmaceuticals, INC. | $23.57 | 2020 | |
| Pfizer INC. | $14.06 | 2019 | |
| Merck Sharp & Dohme LLC | $13.36 | 2019 | |
| Boston Scientific Corporation | $12.67 | 2019 | |
| Eisai INC. | $12.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.31 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $10.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornelius Toma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.